Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Free Subscription

Articles published in Kidney Int

Retrieve available abstracts of 64 articles:
HTML format

Single Articles

    July 2020
  1. LIU X, Ducasa GM, Mallela SK, Kim JJ, et al
    Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport Syndrome.
    Kidney Int. 2020 Jul 30. pii: S0085-2538(20)30837.
    PubMed     Abstract available

  2. IHARA K, Skupien J, Krolewski B, Md Dom ZI, et al
    A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.
    Kidney Int. 2020 Jul 24. pii: S0085-2538(20)30834.
    PubMed     Abstract available

  3. DE BOER IH, Caramori ML, Chan JCN, Heerspink HJL, et al
    TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment.
    Kidney Int. 2020 Jul 10. pii: S0085-2538(20)30798.
    PubMed     Abstract available

    Founding papers of current nephrology: from acute kidney injury to diabetic kidney disease.
    Kidney Int. 2020;98:6-9.

    May 2020
  5. LI J, Neal B, Perkovic V, de Zeeuw D, et al
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
    Kidney Int. 2020 May 26. pii: S0085-2538(20)30565.
    PubMed     Abstract available

    Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?
    Kidney Int. 2020;97:855-857.
    PubMed     Abstract available

  7. Corrigendum to "van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients
    Kidney Int. 2020;97:1061.

    April 2020
  8. LAI H, Chen A, Cai H, Fu J, et al
    Podocyte and endothelial-specific elimination of BAMBI identifies differential transforming growth factor-beta pathways contributing to diabetic glomerulopathy.
    Kidney Int. 2020 Apr 26. pii: S0085-2538(20)30429.
    PubMed     Abstract available

  9. HESP AC, Schaub JA, Prasad PV, Vallon V, et al
    The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
    Kidney Int. 2020 Apr 26. pii: S0085-2538(20)30419.
    PubMed     Abstract available

  10. JIA C, Ke-Hong C, Fei X, Huan-Zi D, et al
    Decoy receptor 2 mediation of the senescent phenotype of tubular cells by interacting with peroxiredoxin 1 presents a novel mechanism of renal fibrosis in diabetic nephropathy.
    Kidney Int. 2020 Apr 24. pii: S0085-2538(20)30405.
    PubMed     Abstract available

  11. Corrigendum to "Townsend RR, Guarnieri P, Argyropoulos C, et al.; on behalf of the TRIDENT Study Investigators. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study." Kidney Int. 2020;97:10-13.
    Kidney Int. 2020;97:809.

  12. VAN BOMMEL EJM, Lytvyn Y, Perkins BA, Soleymanlou N, et al
    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
    Kidney Int. 2020;97:631-635.

    February 2020
  13. BJORNSTAD P, Nehus E, Jenkins T, Mitsnefes M, et al
    Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes.
    Kidney Int. 2020 Feb 3. pii: S0085-2538(20)30114.
    PubMed     Abstract available

  14. SUGAHARA M, Tanaka T, Nangaku M
    Modulating the immune system to delay the clinical onset of type 1 diabetes.
    Kidney Int. 2020;97:248-250.

  15. SALEHI T, Coates PT
    Class effect: dapagliflozin reduces cardiovascular and kidney events.
    Kidney Int. 2020;97:246-248.

    January 2020
  16. BJORNSTAD P, Nelson RG, Pavkov ME
    Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
    Kidney Int. 2020;97:31-33.
    PubMed     Abstract available

  17. LEON-JIMENEZ D, Moreno-Obregon F, Beltran-Romero LM, Miramontes-Gonzalez JP, et al
    Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
    Kidney Int. 2020;97:213.

  18. TOWNSEND RR, Guarnieri P, Argyropoulos C, Blady S, et al
    Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study.
    Kidney Int. 2020;97:10-13.

  19. MAYER GJ, Wanner C, Weir MR, Inzucchi SE, et al
    The authors reply.
    Kidney Int. 2020;97:213-214.

    December 2019
  20. HASEGAWA S, Tanaka T, Saito T, Fukui K, et al
    The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
    Kidney Int. 2019 Dec 25. pii: S0085-2538(19)31247.
    PubMed     Abstract available

    Prediabetes after kidney transplantation-a reason to worry?
    Kidney Int. 2019;96:1280-1282.
    PubMed     Abstract available

    November 2019
  22. RAMNATH RD, Butler MJ, Newman G, Desideri S, et al
    Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease.
    Kidney Int. 2019 Nov 2. pii: S0085-2538(19)31110.
    PubMed     Abstract available

    October 2019
  23. LIANG X, Wang P, Chen B, Ge Y, et al
    Glycogen synthase kinase 3beta hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease.
    Kidney Int. 2019 Oct 10. pii: S0085-2538(19)30992.
    PubMed     Abstract available

  24. VAN BOMMEL EJM, Muskiet MHA, van Baar MJB, Tonneijck L, et al
    The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    Kidney Int. 2019 Oct 10. pii: S0085-2538(19)30991.
    PubMed     Abstract available

  25. ITO M, Nangaku M
    Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
    Kidney Int. 2019;96:823-825.
    PubMed     Abstract available

  26. MARQUEZ A, Batlle D
    Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?
    Kidney Int. 2019;96:815-817.
    PubMed     Abstract available

  27. NISHI H, Nangaku M
    Podocyte lipotoxicity in diabetic kidney disease.
    Kidney Int. 2019;96:809-812.

    September 2019
  28. VERMA N, Liu M, Ly H, Loria A, et al
    Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries.
    Kidney Int. 2019 Sep 5. pii: S0085-2538(19)30844.
    PubMed     Abstract available

    Said the glucose sensor to the insulin pump: can glycemic control be improved in hospitalized ESRD patients with diabetes mellitus?
    Kidney Int. 2019;96:540-542.
    PubMed     Abstract available

    August 2019
  30. KAMMER M, Heinzel A, Willency JA, Duffin KL, et al
    Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes.
    Kidney Int. 2019 Aug 30. pii: S0085-2538(19)30841.
    PubMed     Abstract available

  31. VAN BAAR MJB, Scholtes RA, van Raalte DH
    SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.
    Kidney Int. 2019;96:283-286.
    PubMed     Abstract available

    July 2019
  32. KANDA E, Nangaku M
    Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
    Kidney Int. 2019;96:8-10.

    June 2019
  33. ZHANG D, Gava AL, Van Krieken R, Mehta N, et al
    The caveolin-1 regulated protein follistatin protects against diabetic kidney disease.
    Kidney Int. 2019 Jun 17. pii: S0085-2538(19)30618.
    PubMed     Abstract available

    May 2019
  34. BALMER LA, Whiting R, Rudnicka C, Gallo LA, et al
    Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease.
    Kidney Int. 2019 May 30. pii: S0085-2538(19)30510.
    PubMed     Abstract available

  35. KODAMA Y, Hyodo F, Yamato M, Yasukawa K, et al
    Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice.
    Kidney Int. 2019 May 24. pii: S0085-2538(19)30515.
    PubMed     Abstract available

  36. ROSSING P, Block GA, Chin MP, Goldsberry A, et al
    Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
    Kidney Int. 2019 May 16. pii: S0085-2538(19)30503.
    PubMed     Abstract available

  37. CHO ME, Hansen JL, Peters CB, Cheung AK, et al
    An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease.
    Kidney Int. 2019 May 15. pii: S0085-2538(19)30506.
    PubMed     Abstract available

  38. CASSIS P, Locatelli M, Corna D, Villa S, et al
    Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.
    Kidney Int. 2019 May 10. pii: S0085-2538(19)30486.
    PubMed     Abstract available

    April 2019
  39. BARBOUR S, Djurdjev O, Gill JS, Dong JJ, et al
    A propensity score matched analysis shows no adverse effect of early steroid withdrawal in non-diabetic kidney transplant recipients with and without glomerulonephritis.
    Kidney Int. 2019 Apr 1. pii: S0085-2538(19)30388.
    PubMed     Abstract available

    March 2019
  40. MAYER GJ, Wanner C, Weir MR, Inzucchi SE, et al
    Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
    Kidney Int. 2019 Mar 21. pii: S0085-2538(19)30317.
    PubMed     Abstract available

  41. BALLY L, Gubler P, Thabit H, Hartnell S, et al
    Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis.
    Kidney Int. 2019 Mar 20. pii: S0085-2538(19)30322.
    PubMed     Abstract available

  42. LAVOZ C, Matus YS, Orejudo M, Carpio JD, et al
    Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.
    Kidney Int. 2019 Mar 8. pii: S0085-2538(19)30124.
    PubMed     Abstract available

  43. CHEN G, Chen H, Ren S, Xia M, et al
    Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease.
    Kidney Int. 2019 Mar 7. pii: S0085-2538(19)30273.
    PubMed     Abstract available

  44. SUNG CC, Chen L, Limbutara K, Jung HJ, et al
    RNA-Seq and protein mass spectrometry in microdissected kidney tubules reveal signaling processes initiating lithium-induced nephrogenic diabetes insipidus.
    Kidney Int. 2019 Mar 4. pii: S0085-2538(19)30267.
    PubMed     Abstract available

    February 2019
  45. XU H, Kuja-Halkola R, Chen X, Magnusson PKE, et al
    Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding.
    Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30047.
    PubMed     Abstract available

  46. CHEN X, Han Y, Gao P, Yang M, et al
    Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy.
    Kidney Int. 2019 Feb 12. pii: S0085-2538(18)30899.
    PubMed     Abstract available

    TRPC6 in diabetic kidney disease: good guy or bad guy?
    Kidney Int. 2019;95:256-258.
    PubMed     Abstract available

    January 2019
  48. CANI PD
    Targeting gut microbiota with a complex mix of dietary fibers improves metabolic diseases.
    Kidney Int. 2019;95:14-16.

    December 2018
  49. CHAUHAN K, Verghese DA, Rao V, Chan L, et al
    Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes.
    Kidney Int. 2018 Dec 20. pii: S0085-2538(18)30772.
    PubMed     Abstract available

  50. HIRAKAWA Y, Nangaku M
    Targeting oxidative stress in diabetic kidney disease: a novel drug in an old pathway.
    Kidney Int. 2018;94:1038-1039.

    November 2018
  51. JIANG G, Luk AOY, Tam CHT, Xie F, et al
    Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.
    Kidney Int. 2018 Nov 2. pii: S0085-2538(18)30629.
    PubMed     Abstract available

    September 2018
  52. MICAKOVIC T, Papagiannarou S, Clark E, Kuzay Y, et al
    The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus.
    Kidney Int. 2018 Sep 3. pii: S0085-2538(18)30442.
    PubMed     Abstract available

    July 2018
  53. TANAKA S, Sugiura Y, Saito H, Sugahara M, et al
    Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
    Kidney Int. 2018 Jul 13. pii: S0085-2538(18)30353.
    PubMed     Abstract available

    June 2018
  54. BOMSZTYK K, Denisenko O, Wang Y
    DNA methylation yields epigenetic clues into the diabetic nephropathy of Pima Indians.
    Kidney Int. 2018;93:1272-1275.
    PubMed     Abstract available

    May 2018
  55. FU J, Wei C, Zhang W, Schlondorff D, et al
    Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice.
    Kidney Int. 2018 May 31. pii: S0085-2538(18)30242.
    PubMed     Abstract available

  56. GROVE KJ, Lareau NM, Voziyan PA, Zeng F, et al
    Imaging mass spectrometry reveals direct albumin fragmentation within the diabetic kidney.
    Kidney Int. 2018 May 17. pii: S0085-2538(18)30202.
    PubMed     Abstract available

    February 2018
  57. HONG Q, Zhang L, Das B, Li Z, et al
    Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury.
    Kidney Int. 2018 Feb 22. pii: S0085-2538(18)30033.
    PubMed     Abstract available

  58. KOPP C, Linz P, Maier C, Wabel P, et al
    Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by (23)Na magnetic resonance imaging.
    Kidney Int. 2018 Feb 15. pii: S0085-2538(17)30857.
    PubMed     Abstract available

  59. NOWAK N, Skupien J, Smiles AM, Yamanouchi M, et al
    Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.
    Kidney Int. 2018 Feb 2. pii: S0085-2538(17)30892.
    PubMed     Abstract available

  60. PERCO P, Mayer G
    Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?
    Kidney Int. 2018;93:308-310.
    PubMed     Abstract available

    January 2018

  61. Zhang L, Zhang Q, Liu S, et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney Int. 2017;92:140-153.
    Kidney Int. 2018;93:271.

    December 2017
  62. XIE Y, Bowe B, Li T, Xian H, et al
    Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus.
    Kidney Int. 2017 Dec 7. pii: S0085-2538(17)30676.
    PubMed     Abstract available

    October 2017
  63. NAIR V, Komorowsky CV, Weil EJ, Yee B, et al
    A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome.
    Kidney Int. 2017 Oct 18. pii: S0085-2538(17)30610.
    PubMed     Abstract available

  64. CHUN N, Wyatt CM, He JC
    Identification of a protective proteomic signature and a potential therapeutic target in diabetic nephropathy.
    Kidney Int. 2017;92:780-781.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.